Rodman & Renshaw Upgrades Rating on Sequenom's Stock

Despite the upgrade, an analyst expressed concern about the commercial value of the test, noting the cost involved.

Full-text access for registered users only. Existing users login here.
New to GenomeWeb? Register here quickly for free access.